150349-36-3

Basic information

• Product Name: tert-Butyl N-(3-aminopropyl)-N-methylcarbamate
• Synonyms: N-(3-AMINO-PROPYL)-N-METHYLCARBAMIC ACID T-BUTYL ESTER;N-(3-AMINOPROPYL)-N-METHYLCARBAMIC ACID TERT-BUTYL ESTER;N-(4-AMINOPROPYL)-N-METHYL CARBAMIC ACID TERT-BUTYL ESTER;1-N-BOC-1-N-METHYL-1,3-DIAMINOPROPANE;(3-AMINO-PROPYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER;BUTTPARK 90\06-20;BOC-N-ME-1,3-DIAMINOPROPANE;N-(3-Aminopropyl)-N-methylcarbamic acid tert-butyl
• CAS NO: 150349-36-3
• Molecular Formula: C₉H₂₀N₂O₂
• Molecular Weight: 188.27
• Mol File: 150349-36-3.mol

Chemical Properties

• Boiling Point: 254.609 °C at 760 mmHg
• Flash Point: 107.784 °C
• Appearance: Pale yellow/Liquid
• Density: 0.982 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.06±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: tert-Butyl N-(3-aminopropyl)-N-methylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl N-(3-aminopropyl)-N-methylcarbamate(150349-36-3)
• EPA Substance Registry System: tert-Butyl N-(3-aminopropyl)-N-methylcarbamate(150349-36-3)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 150349-36-3(Hazardous Substances Data)

Upstream product

• 115465-11-7 [3-(1,3-dioxo-1,3-dihydroisoindol-2-yl)propyl]carbamic acid tert-butyl ester 
• 74-88-4 methyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6291-84-5 N-Methyl-1,3-propanediamine 
• 1198081-75-2 N1-tert-butoxycarbonyl-N1-methyl-N2-phthalyl-1,3-propanediamine 

Downstream Products

• 859828-47-0 {3-[(R)-2-(4-isobutylphenyl)propionylamino]propyl}methylcarbamic acid tert-butyl ester 
• 110-86-1 pyridine 
• 209733-77-7 N-(Methyl)-N-[3-[(4-cyanophenyl)carbonylamino]propyl]carbamic acid 1,1-dimethylethyl ester 
• 878798-77-7 phenylmethyl-[(1S)-1-(cyclohexylmethyl)-2-({3-[{[(1,1-dimethylethyl)oxy]carbonyl}(methyl)amino]propyl}amino)-2-oxoethyl]carbamate 
• 878798-81-3 N₁-{3-[{[(1,1-dimethylethyl)oxy]carbonyl}(methyl)amino]propyl}-N₂-{[(phenylmethyl)oxy]carbonyl}-L-leucinamide 
• 945021-12-5 [3-(2-chloro-6-nitro-phenylamino)-propyl]-methyl-carbamic acid tert-butyl ester 
• 1033225-39-6 tert-butyl (3-((2-nitro-4-fluorophenyl)amino)propyl)methylcarbamate 
• 1093799-99-5 C₁₅H₂₃N₅O₃ 
• 765961-90-8 C₁₆H₂₆N₂O₂ 
• 1111236-89-5 C₁₆H₂₄ClN₅O₂ 
• 1351278-82-4 methyl 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(3-(tert-butoxycarbonyl(methyl)amino)propylcarbamoyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-H-cyclopenta[a]chrysen-9-yl)benzoate 
• 1448692-36-1 C₁₈H₂₅BN₄O₅ 
• 1448724-44-4 methyl 2-benzyl-4-((3-((tert-butoxycarbonyl)(methyl)amino)propyl)amino)-9H-pyrimido[4,5-b]indole-7-carboxylate 

Relevant articles and documents

Bis(acridinylthiourea)platinum(II) complexes: Synthesis, DNA affinity, and biological activity in glioblastoma cells

The preparation of two novel bis(acridine)platinum(II) complexes is reported. The 4+ charged conjugates associate strongly with double-stranded native DNA (Ki>106), possibly through bisintercalation. A cell viability assay was used to demonstrate that both compounds are capable of mediating cytotoxicity at micromolar concentrations in SNB19 brain tumor cells.

3,4-DIHYDROQUINAZOLINE DERIVATIVE AND COMBINATION COMPRISING THE SAME

A 3,4-dihydroquinazoline derivative or a pharmaceutically acceptable salt thereof and a composition containing the same are provided. The 3,4-dihydroquinazoline derivative or a pharmaceutically acceptable salt thereof show activities of blocking an intrac

In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells

As a result of our continuous research, new 3,4-dihydroquinazoline derivative containing ureido group, KCP10043F was synthesized and evaluated for T-type Ca2+channel (Cav3.1) blockade, cytotoxicity, and cell cycle arrest against huma

Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist

The anti-proliferative and apoptotic activities of new T-type calcium channel antagonist, 6e (BK10040) on human lung adenocarcinoma A549 cells were investigated. The MTT assay results indicated that BK10040 was cytotoxic against human lung adenocarcinoma (A549) and pancreatic cancer (MiaPaCa2) cells in a dose-dependent manner with IC50 of 2.25 and 0.93 μM, respectively, which is ca. 2-fold more potent than lead compound KYS05090 despite of its decreased T-type calcium channel blockade. As a mode of action for cytotoxic effect of BK10040 on lung cancer (A549) cells, this cancer cell death was found to have the typical features of apoptosis, as evidenced by the accumulation of positive cells for annexin V. In addition, BK10040 triggered the activations of caspases 3 and 9, and the cleavages of poly (ADP-ribose) polymerase (PARP). Moreover, the treatment with z-VAD-fmk (a broad spectrum caspase inhibitor) significantly prevented BK10040-induced apoptosis. Based on these results, BK10040 may be used as a potential therapeutic agent for human lung cancer via the potent apoptotic activity.

COMPOUNDS AND METHODS

Disclosed are compounds having formula I, wherein X1, X2, X3, R1, R2, R3, R4, R5, Y, A, Z, L, m and n are as defined herein, and methods of making and using the same.

2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors

The CXC chemokine CXCL8/IL-8 plays a major role in the activation and recruitment of polymorphonuclear (PMN) cells at inflammatory sites. CXCL8 activates PMNs by binding the seven-transmembrane (7-TM) G-protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2). (R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCLS-induced human PMNs chemotaxis. We report here molecular modeling studies showing a putative interaction site of 1 in the TM region of CXCR1. The binding model was confirmed by alanine scanning mutagenesis and photoaffinity labeling experiments. The molecular model driven medicinal chemistry optimization of 1 led to a new class of potent and specific inhibitors of CXCL8 biological activity. Among these, repertaxin (13) was selected as a clinical candidate drug for prevention of post-ischemia reperfusion injury.

Nonpeptide inhibitors of cathepsin G: Optimization of a novel β-ketophosphonic acid lead by structure-based drug design

The serine protease cathepsin G (EC 3.4.21.20; Cat G), which is stored in the azurophilic granules of neutrophils (polymorphonuclear leukocytes) and released on degranulation, has been implicated in various pathological conditions associated with inflammation. By employing high-throughput screening, we identified β-ketophosphonic acid 1 as a moderate inhibitor of Cat G (IC50 = 4.1 μM). We were fortunate to obtain a cocrystal of 1 with Cat G and solve its structure by X-ray crystallography (3.5 A). Structural details from the X-ray analysis of 1·Cat G served as a platform for optimization of this lead compound by structure-based drug design. With the aid of molecular modeling, substituents were attached to the 3-position of the 2-naphthyl ring of 1, which occupies the S1 pocket of Cat G, to provide an extension into the hydrophobic S3 region. Thus, we arrived at analogue 7 with an 80-fold potency improvement over 1 (IC50 = 53 nM). From these results, it is evident that the β-ketophosphonic acid unit can form the basis for a novel class of serine protease inhibitors. Copyright

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists of the STR1 are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets wherein G is: STR2 for example, STR3

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists of the formula: STR1 are disclosed for use in inhibiting the aggregation of blood platelets. wherein G is: STR2